OBJECTIVES: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. METHODS: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). RESULTS: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with K(i) values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. CONCLUSIONS: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.
OBJECTIVES: As an initial step in developing novel antibacterials against Burkholderia pseudomallei, we have characterized the FabI enoyl-ACP reductase homologues in the type II fatty acid biosynthesis pathway from this organism and performed an initial enzyme inhibition study. METHODS: A BLAST analysis identified two FabI enoyl-ACP reductase homologues, bpmFabI-1 and bpmFabI-2, in the B. pseudomallei genome, which were cloned, overexpressed in Escherichia coli and purified. Steady-state kinetics was used to determine the reaction mechanism and the sensitivity of bpmFabI-1 to four diphenyl ether FabI inhibitors. The antibacterial activity of the inhibitors was assessed using a wild-type strain of Burkholderia thailandensis (E264) and an efflux pump mutant (Bt38). RESULTS: Consistent with its annotation as an enoyl-ACP reductase, bpmFabI-1 catalysed the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism. In contrast, bpmFabI-2 was inactive with all substrates tested and only bpmfabI-1 was transcriptionally active under the growth conditions employed. The sensitivity of bpmFabI-1 to four diphenyl ethers was evaluated and in each case the compounds were slow-onset inhibitors with K(i) values of 0.5-2 nM. In addition, triclosan and PT01 had MIC values of 30 and 70 mg/L for B. pseudomallei as well as a wild-type strain of B. thailandensis (E264), but MIC values of <1 mg/L for the efflux pump mutant Bt38. A reduction in MIC values was also observed for the pump mutant strain with the other diphenyl ethers. CONCLUSIONS: Provided that efflux can be circumvented, bpmFabI-1 is a suitable target for drug discovery.
Authors: C W Levy; A Roujeinikova; S Sedelnikova; P J Baker; A R Stuitje; A R Slabas; D W Rice; J B Rafferty Journal: Nature Date: 1999-04-01 Impact factor: 49.962
Authors: Nathan A Groathouse; Susan E Brown; Dennis L Knudson; Patrick J Brennan; Richard A Slayden Journal: J Clin Microbiol Date: 2006-04 Impact factor: 5.948
Authors: W H Ward; G A Holdgate; S Rowsell; E G McLean; R A Pauptit; E Clayton; W W Nichols; J G Colls; C A Minshull; D A Jude; A Mistry; D Timms; R Camble; N J Hales; C J Britton; I W Taylor Journal: Biochemistry Date: 1999-09-21 Impact factor: 3.162
Authors: Brian D Ames; Chi Nguyen; Joel Bruegger; Peter Smith; Wei Xu; Suzanne Ma; Emily Wong; Steven Wong; Xinkai Xie; Jesse W-H Li; John C Vederas; Yi Tang; Shiou-Chuan Tsai Journal: Proc Natl Acad Sci U S A Date: 2012-06-25 Impact factor: 11.205
Authors: Luke C Kingry; Jason E Cummings; Kerry W Brookman; Gopal R Bommineni; Peter J Tonge; Richard A Slayden Journal: J Bacteriol Date: 2012-11-09 Impact factor: 3.490
Authors: Johannes Schiebel; Andrew Chang; Sonam Shah; Yang Lu; Li Liu; Pan Pan; Maria W Hirschbeck; Mona Tareilus; Sandra Eltschkner; Weixuan Yu; Jason E Cummings; Susan E Knudson; Gopal R Bommineni; Stephen G Walker; Richard A Slayden; Christoph A Sotriffer; Peter J Tonge; Caroline Kisker Journal: J Biol Chem Date: 2014-04-16 Impact factor: 5.157
Authors: Jason E Cummings; Adam J Beaupre; Susan E Knudson; Nina Liu; Weixuan Yu; Carla Neckles; Hui Wang; Avinash Khanna; Gopal R Bommineni; Lily A Trunck; Herbert P Schweizer; Peter J Tonge; Richard A Slayden Journal: Antimicrob Agents Chemother Date: 2013-12-30 Impact factor: 5.191
Authors: Jason E Cummings; Luke C Kingry; Drew A Rholl; Herbert P Schweizer; Peter J Tonge; Richard A Slayden Journal: Antimicrob Agents Chemother Date: 2013-11-25 Impact factor: 5.191